# Tolerance and Oncological Outcomes of In-Field Reirradiation for Locally Recurrent Breast Cancer: A Long-Term Single-Center Experience

Jérémy Baude, Rémi Dendale, Kim I. Cao, Alain Fourquet, Youlia M. Kirova

► To cite this version:

Jérémy Baude, Rémi Dendale, Kim I. Cao, Alain Fourquet, Youlia M. Kirova. Tolerance and Oncological Outcomes of In-Field Reirradiation for Locally Recurrent Breast Cancer: A Long-Term Single-Center Experience. Cancers, 2023, 15 (18), 10.3390/cancers15184515. [https://doi.org/10.3390/cancers15184515](https://doi.org/10.3390/cancers15184515)

HAL Id: hal-04334570

https://hal.science/hal-04334570v1

Submitted on 21 Dec 2023

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons CC BY 4.0 - Attribution - International License
Article

# Tolerance and Oncological Outcomes of In-Field Reirradiation for Locally Recurrent Breast Cancer: A Long-Term Single-Center Experience

Jérémy Baude<fnref n="1" />, Rémi Dendale<fnref n="1" />, Kim Cao<fnref n="1" /> ID, Alain Fourquet<fnref n="1" /> and Youlia Kirova <fnref n="1" />,<fnref n="2" />,* ID

**Simple Summary:** Breast reirradiation could represent a valuable option for local recurrence of breast cancer in previously irradiated sites. We aimed to report on the efficacy and tolerability of this treatment in our institution. The results of this series combined with those available in the literature indicate that breast/chest wall reirradiation is feasible with good oncological results and low toxicity rates.

**Abstract:** Background: The management of cancer relapse in previously irradiated tissues is a challenging therapeutic issue. The aim of this work was to report our experience with breast reirradiation for locoregionally recurrent breast cancer. Methods: All patients who underwent breast or chest wall in-field reirradiation at the Institut Curie, Paris, France, between 2003 and 2019, were identified. Efficacy outcomes and physician-reported toxicities were retrospectively assessed. Results: A total of 21,372 patients underwent breast irradiation in our institution. Of these, 28 received a second course of radiotherapy to the homolateral breast/chest wall. A total of 18 (64%) patients were treated with a curative intent, and 10 (36%) were treated for palliative purposes. Only one acute and one late grade 3 adverse events were reported. One patient with major cardiovascular risk factors died of myocardial infarction 13 months after left breast reirradiation. The 2-year LRFS, OS, DSS, PFS and MFS were 59%, 79%, 82%, 46% and 75%, respectively, in the whole cohort. The 2-year LRFS (72% vs. 31%, *p* = 0.02), OS (94% vs. 50%, *p* < 0.01), DSS (94% vs. 56%, *p* < 0.01) and PFS (61% vs. 20%, *p* = 0.02) differed significantly between patients treated with curative or palliative intent but not the MFS (78% vs. 69%, *p* = 0.77). Among the patients, eight (29%) remained relapse-free 5 years after reirradiation. Conclusion: Breast/chest wall reirradiation appears to be feasible with good disease control, especially in patients treated with a curative intent, and presents acceptable toxicity rates.

**Keywords:** breast cancer; radiation therapy; recurrence; reirradiation; toxicity; efficacy

<figure><img src="image_2.png" /></figure>

check for
updates

**Citation:** Baude, J.; Dendale, R.; Cao, K.; Fourquet, A.; Kirova, Y. Tolerance and Oncological Outcomes of In-Field Reirradiation for Locally Recurrent Breast Cancer: A Long-Term Single-Center Experience.
*Cancers* **2023**, *15*, 4515. https://doi.org/10.3390/cancers15184515

Academic Editor: Hideya Yamazaki

Received: 11 August 2023

Revised: 4 September 2023

Accepted: 7 September 2023

Published: 12 September 2023

<figure><img src="image_3.png" /></figure>

**Copyright:** © 2023 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).

## 1. Introduction

In recent years, improved management of localized and locally advanced breast cancer has led to a decreased rate of locoregional cancer recurrence after breast-conserving surgery followed by adjuvant radiation therapy (RT). However, approximately 8% of patients still develop an ipsilateral breast relapse [1]. Treatment of this recurrence in previously irradiated sites is intricate and often relies on total mastectomy and systemic treatments [2].

Reirradiation could represent a valuable therapeutic option in this setting, especially in patients who seek second partial breast surgery but also in patients who require palliative local treatment. In both cases, reirradiation raises a number of issues concerning its feasibility, efficacy and toxicity [3]. Therefore, the selection of eligible patients remains a challenge and often relies on a case-by-case medical collegial decision. Different doses, RT techniques, and radiation fields have been previously reported. Since the first series

<footnote n="1">¹ Department of Radiation Oncology, Institut Curie, 75005 Paris, France; jbaude@cgfl.fr (J.B.); remi.dendale@curie.fr (R.D.); kim.cao@curie.fr (K.C.); alain.fourquet@curie.fr (A.F.)</footnote>

<footnote n="2">² UFR Santé, Versailles Saint-Quentin-en-Yvelines University, 78180 Saint Quentin-en-Yvelines, France</footnote>

<footnote>* Correspondence: youlia.kirova@curie.fr</footnote>
published in the literature showed positive signals for local reirradiation [4,5], systemic treatments as well as RT techniques have evolved greatly. More recently, some have studied the role of reirradiation with concurrent hyperthermia [6–8], while others have found favourable results with partial external beam reirradiation [9,10]. Proton therapy is another investigated therapeutic weapon [11,12]. Although efficacy outcomes are excellent, with acceptable toxicity, only short-term results are currently available. On the other hand, Hannoun-Levi et al. recently reported long-term outcomes of a second conservative treatment consisting of a lumpectomy and breast brachytherapy: toxicity was low and 10-year DFS was 78% [13].

However, most of these techniques evaluated (hyperthermia, proton therapy, brachytherapy) are only available in a limited number of tertiary facilities, and data on "regular" radiation therapy, defined as feasible in most radiotherapy centres, are still scarce.

Therefore, the purpose of this study was not only to evaluate the toxicity and the feasibility of in-field reirradiation in real-life patients, but also to report the long-term results of this treatment option, in the modern era of systemic and targeted therapies. We also provide additional data about locoregional recurrences and their management in a French single centre.

**2. Materials and Methods**

**2.1. Patients**

This retrospective study was conducted at the Institut Curie, Paris. It included adult patients who underwent two courses of RT delivered to the breast/chest wall (in-field reirradiation) ± lymph nodes with curative or palliative intent between 2003 and 2019. Those who underwent reirradiation only in volumes other than the ipsilateral breast/chest wall were excluded for the purpose of relevant toxicity evaluation.

**2.2. Data Extraction and Collection**

A complete medical search for all patients who fit the inclusion criteria was performed within our institution. They were further classified according to whether the purpose of reirradiation was curative or palliative.

Physician-reported acute (during radiotherapy and the first 6 months following the end of RT) and late (later than 6 months after RT) toxicities were assessed using the common terminology criteria for adverse events (CTCAE) 5.0.

Efficacy outcomes were evaluated through local recurrence-free survival (LRFS), progression-free survival (PFS), overall survival (OS), disease-specific survival (DSS), and metastasis-free survival (MFS). Progression-free survival was defined as the period of time from reirradiation to disease recurrence, progression and death. Overall survival was the time from reirradiation to death of any cause. Disease-specific survival (DSS) accounted for the time from the second course of RT to death from breast cancer. Local recurrence-free survival (LRFS) and metastasis-free survival (MFS) were defined as the time from treatment to local recurrence and metastatic relapse, respectively. Progression was defined as the earliest evidence of radiological progression or clinical progression according to the occurrence or reappearance of disease-related symptoms.

When RT was delivered in a hypofractionated regimen, the equivalent dose in 2 Gy (EQD2, in Gy₂) was calculated using an α/β = 3 Gy [14]. The cumulative dose was defined as the sum of the highest dose prescribed in each RT course, including the boost.

**2.3. Statistical Analysis**

Descriptive analyses were performed using medians with interquartile ranges (IQR) for quantitative variables and percentages for qualitative variables. Survival rates and medians were determined using the Kaplan–Meier method. Survival curves were compared with the Grehan–Breslow–Wilcoxon test. Median follow-up was determined using the reverse Kaplan–Meier method. Tests were two-sided. *p* values less than 0.05 were considered significant. Analyses were performed using GraphPad Prism 9.4 software.
# 3. Results

## 3.1. *Description of the Cohort*

Between 2003 and 2019, we identified 21,372 patients who underwent breast or chest wall irradiation with or without lymph nodes in our institution. Of these, 460 (2.15%) received a second irradiation to the contralateral breast and/or lymph nodes, 107 (0.5%) to the homolateral lymph nodes without breast/chest wall reirradiation because only regional recurrence occurred in patients already treated locally, and only 28 (0.13%) received a second course of in-field reirradiation to the homolateral breast or chest wall (Figure 1). These 28 patients were included in this study. All of them were female.

<figure><img src="image_4.png" /><figcaption>**Figure 1.** Flow chart of the studied population. RT: radiotherapy.</figcaption></figure>

### 3.1.1. Patient Characteristics at First Irradiation

Patient characteristics at first irradiation are given in Table 1. The median age was 57 (IQR, 44–70.5) years. Before radiotherapy, seven (25%) women underwent total mastectomy, and 18 (61%) underwent lumpectomy. Four (14%) patients had only a biopsy, as one had her first course of RT given for postmastectomy recurrence at 19 years, one refused surgery, one was rejected for surgery because of age (80 years old) and received hormone therapy and RT only, and one underwent palliative RT. Radiotherapy was normofractionated in all patients. The standard protocol was 50 Gy/25 fractions to the chest wall +/- lymph nodes or 50 Gy/25 fractions to the breast, followed by a sequential normofractionated boost to the tumor bed. The median dose was 56 (range, 50–66) Gy₂, including the boost. A total of 14 patients received a sequential boost of 10 Gy in 5 fractions (n = 2), 16 Gy in 8 fractions (n = 10) and up to 20 Gy/10 fractions in two patients with advanced disease.
<table><caption>**Table 1.** Patients and treatment characteristics for the first and second RT courses.</caption><thead><tr><th>n = 28</th><th>First RT Course</th><th>Second RT Course</th></tr></thead><tbody><tr><td>Age (years), median (IQR)</td><td>57 (44–70.5)</td><td>63 (49–78)</td></tr><tr><td>Primary surgery (%)</td><td></td><td></td></tr><tr><td>Mastectomy</td><td>6 (22%)</td><td>14 (50%)</td></tr><tr><td>Lumpectomy</td><td>18 (64%)</td><td>6 (21%)</td></tr><tr><td>Biopsy only</td><td>4 (14%)</td><td>3 (11%)</td></tr><tr><td>No surgery</td><td>0</td><td>5 (18%)</td></tr><tr><td>Resection status (%)</td><td></td><td></td></tr><tr><td>R0</td><td>21 (75%)</td><td>14 (70%)</td></tr><tr><td>R1</td><td>2 (7%)</td><td>3 (15%)</td></tr><tr><td>NR</td><td>5 (18%)</td><td>3 (15%)</td></tr><tr><td>Axillary surgery (%)</td><td></td><td></td></tr><tr><td>Axillary lymph node dissection</td><td>18 (64%)</td><td>8 (29%)</td></tr><tr><td>Sentinel lymph node biopsy</td><td>4 (14%)</td><td>3 (11%)</td></tr><tr><td>No axillary surgery</td><td>6 (22%)</td><td>17 (61%)</td></tr><tr><td>Histology (%)</td><td></td><td></td></tr><tr><td>DCIS</td><td>0</td><td>0</td></tr><tr><td>Invasive ductal carcinoma</td><td>22 (79%)</td><td>15 (54%)</td></tr><tr><td>Invasive lobular carcinoma</td><td>5 (18%)</td><td>2 (7%)</td></tr><tr><td>Invasive micropapillary carcinoma</td><td>1 (4%)</td><td>5 (18%)</td></tr><tr><td>Clinical TNM classification (%)</td><td></td><td></td></tr><tr><td>cTx</td><td>1 (4%)</td><td></td></tr><tr><td>cT1</td><td>3 (11%)</td><td></td></tr><tr><td>cT2</td><td>15 (54%)</td><td></td></tr><tr><td>cT3</td><td>2 (7%)</td><td>N/A</td></tr><tr><td>cT4</td><td>7 (25%)</td><td></td></tr><tr><td>cN0</td><td>17 (61%)</td><td></td></tr><tr><td>cN1</td><td>10 (36%)</td><td></td></tr><tr><td>cN2</td><td>1 (4%)</td><td></td></tr><tr><td>cN3</td><td>0</td><td></td></tr><tr><td>Pathological TNM classification (%)</td><td></td><td></td></tr><tr><td>pT0</td><td>2 (7%)</td><td></td></tr><tr><td>pT1</td><td>12 (43%)</td><td></td></tr><tr><td>pT2</td><td>7 (25%)</td><td></td></tr><tr><td>pT3</td><td>0</td><td></td></tr><tr><td>pT4</td><td>2 (7%)</td><td>N/A</td></tr><tr><td>N/A</td><td>5 (18%)</td><td></td></tr><tr><td>pN0</td><td>12 (43%)</td><td></td></tr><tr><td>pN1</td><td>8 (29%)</td><td></td></tr><tr><td>pN2</td><td>3 (11%)</td><td></td></tr><tr><td>pN3</td><td>0</td><td></td></tr><tr><td>No axillary surgery</td><td>5 (18%)</td><td></td></tr><tr><td>AJCC 8th edition stage (cTNM) (%)</td><td></td><td></td></tr><tr><td>I</td><td>4 (14%)</td><td></td></tr><tr><td>II</td><td>16 (57%)</td><td>N/A</td></tr><tr><td>III</td><td>8 (29%)</td><td></td></tr><tr><td>IV</td><td>0</td><td></td></tr><tr><td>Hormone receptor and HER2 status (%)</td><td></td><td></td></tr><tr><td>HR+ HER2- (%)</td><td>16 (57%)</td><td>14 (50%)</td></tr><tr><td>HR+ HER2+ (%)</td><td>1 (4%)</td><td>2 (7%)</td></tr><tr><td>HR- HER2+ (%)</td><td>3 (11%)</td><td>2 (7%)</td></tr><tr><td>TN (%)</td><td>3 (11%)</td><td>2 (7%)</td></tr><tr><td>NR (%)</td><td>5 (18%)</td><td>8 (29%)</td></tr><tr><td>Chemotherapy (%)</td><td></td><td></td></tr><tr><td>Neoadjuvant</td><td>8 (29%)</td><td>2 (7%)</td></tr><tr><td>Adjuvant</td><td>6 (21%)</td><td>14 (50%)</td></tr><tr><td>Both</td><td>4 (14%)</td><td>0</td></tr><tr><td>Without surgery</td><td>0</td><td>1 (4%)</td></tr><tr><td>None</td><td>10 (36%)</td><td>11 (39%)</td></tr></tbody></table>
<table><caption>**Table 1.** *Cont.*</caption><thead><tr><th>n = 28</th><th>First RT Course</th><th>Second RT Course</th></tr></thead><tbody><tr><td>Hormone therapy (%)</td><td></td><td></td></tr><tr><td>Yes</td><td>19 (68%)</td><td>18 (64%)</td></tr><tr><td>None</td><td>9 (32%)</td><td>10 (36%)</td></tr><tr><td>Radiotherapy modality (%)</td><td></td><td></td></tr><tr><td>Photons</td><td>4 (14%)</td><td>8 (29%)</td></tr><tr><td>Electrons</td><td>1 (4%)</td><td>13 (46%)</td></tr><tr><td>Photons + electrons</td><td>12 (43%)</td><td>6 (21%)</td></tr><tr><td>60Cobalt</td><td>3 (11%)</td><td>1 (4%)</td></tr><tr><td>60Cobalt + electrons</td><td>5 (18%)</td><td>0</td></tr><tr><td>NR</td><td>3 (11%)</td><td>0</td></tr><tr><td>Radiotherapy fields (%)</td><td></td><td></td></tr><tr><td>Chest wall</td><td>6 (21%)</td><td>20 (71%)</td></tr><tr><td>Whole/partial breast</td><td>22 (79%)/0</td><td>7 (25%)/1 (4%)</td></tr><tr><td>Berg II-IV</td><td>22 (79%)</td><td>6 (21%)</td></tr><tr><td>Internal mammary chain</td><td>17 (61%)</td><td>5 (18%)</td></tr><tr><td>Axillary region (Berg I)</td><td>7 (25%)</td><td>2 (7%)</td></tr><tr><td>No lymph node irradiation</td><td>6 (21%)</td><td>21 (75%)</td></tr><tr><td>Radiotherapy positioning (%)</td><td></td><td></td></tr><tr><td>Dorsal decubitus</td><td>16 (57%)</td><td>24 (86%)</td></tr><tr><td>Lateral decubitus</td><td>3 (11%)</td><td>2 (7%)</td></tr><tr><td>NR</td><td>9 (32%)</td><td>2 (7%)</td></tr><tr><td>Use of boost (%)</td><td>14 (50%)</td><td>1 (3.5%)</td></tr><tr><td>RT dose with boost (Gy<sub>2</sub>), median (IQR)</td><td>60 (50–66)</td><td>48 (30–50)</td></tr><tr><td>Time from first RT course (months),<br>median (IQR)</td><td colspan="2">47 (22.75–109.5)</td></tr><tr><td>Cumulative RT dose (Gy<sub>2</sub>), median (IQR)</td><td colspan="2">99 (90.6–114.3)</td></tr></tbody></table>

NR: not reported, N/A: not applicable, DCIS: ductal carcinoma in situ, HR: hormone receptors, TN: triple negative.

### 3.1.2. Patient Characteristics at Second Irradiation

Patient characteristics at the second irradiation are given in Table 1. The median age was 63 (IQR 49–78) years. Overall, three (11%) women presented with multiple recurrences before the second course of in-field radiation therapy. A total of 20 (71%) patients underwent salvage surgery before radiation therapy: of these, 14 (50%) had a total mastectomy, 6 (21%) of them underwent a partial breast resection and 3 (11%) had a biopsy only. Of those who underwent biopsy only, 2 had a unique gross nodule biopsy-resection and were subsequently treated for curative purposes. Five (18%) women had a clinical diagnosis of recurrence and were treated with curative intent. The median time between RT courses was 47 (22.75–109.5) months. RT was given for curative and palliative purposes to 18 (64%) and 10 (36%) patients, respectively. A total of 10 patients (36%) presented with a large residual disease before radiation therapy, 9 of whom were treated with palliative intent. The clinical target volume (CTV) included chest wall ± lymph nodes in 20 (71%) patients, whole breast ± lymph nodes in 7 (25%) and partial breast in 1 (4%). Normofractionated RT was given to 26 (93%) patients with a median dose of 48 (30–50) Gy, including boost.

Two patients received hypofractionated radiation therapy (2 × 6.5 Gy and 5 × 4 Gy). One patient received a sequential boost of 16 Gy (8 × 2 Gy). The median dose was 47 (30–50) Gy<sub>2</sub>, including the boost. The median cumulative dose was 99 (90.6–114.3) Gy<sub>2</sub>.

### 3.2. Reirradiation Toxicity Outcomes

The maximum grade of observed acute toxicity described was grade 1 in 14 (50%) patients, grade 2 in 9 (32.2%) and grade 3 in only one (3.5%) patient, as shown in Figure 2A. No grade 4 acute toxicity was found in our series. The most common adverse events (AEs) were radiodermatitis and pain, which were observed in 24 (85.7%) and 11 (39%) patients, respectively. The maximum grade late toxicity was grade 1 in 15 (54%) patients, grade 2 in five (18%), grade 3 in one patient (3.5%) and grade 5 in one (3.5%). The results are given in
Figure 2B. The side effects were mostly skin fibrosis and skin telangiectasia. There was no brachial plexopathy, lung fibrosis or lymphedema in these series.

<figure><img src="image_5.png" /><figcaption>**Figure 2.** Maximum all-cause acute (A) and late (B) physician-reported toxicity after breast/chest wall reirradiation. Toxicity was evaluated according to the common terminology criteria for adverse events (CTCAE) 5.0.</figcaption></figure>

The patient reported with grade 5 toxicity was a patient with multiple cardiovascular risk factors (unbalanced type 2 diabetes, severe obesity (BMI = 33.7 kg/m⁻²), treated hypertension and treated dyslipidemia) who died of myocardial infarction 13 months after left breast reirradiation for palliative purposes. The first RT course dose to the breast was 50 Gy with an additional sequential boost of 16 Gy, but this 3D conformal irradiation was realized in the lateral position, and the dose to the heart was close to 0 Gy. The patient also received a 3D conformal regional lymph node irradiation. Reirradiation to the chest wall and axilla was realized using the IMRT technique by tomotherapy and delivered 30 Gy/15 fractions, bringing the cumulative dose to 96 Gy₂. (Mean heart dose = 6.86 Gy) The period between the first and second irradiations was 111 months. Systemic treatments consisted of adjuvant FEC75 (fluorouracil, epirubicin, cyclophosphamide) at initial management followed by 5 years of tamoxifen and post-RT docetaxel and fulvestrant at relapse.

### 3.3. Reirradiation Efficacy Outcomes

The median follow-up from completion of the in-field reirradiation was 45.5 (range, 33.5–79.8) months. In the whole cohort, the 2-year LRFS (A), PFS (B), OS (C), DSS (D) and MFS (E) were 59%, 46%, 79%, 82% and 75%, respectively (Figure 3). Two-year LRFS was significantly better in patients treated with curative intent than in those treated with palliative intent (72% vs. 31%, *p* = 0.02), as was the 2-year PFS (61% vs. 20%, *p* = 0.02), as well as the 2-year OS (94% vs. 50%, *p* < 0.01) and the 2-year DSS (94% vs. 56%, *p* < 0.01). However, the 2-year MFS was not significantly different between the groups (78% vs. 69%, *p* = 0.77). Furthermore, we did not find any significant difference in LRFS depending on the efficacy of the first course of RT or the time between the first RT course and reirradiation (Supplementary Figures S1 and S2). Among patients treated in a palliative setting (*n* = 10), 7 (70%) had a clinical improvement after the completion of reirradiation.
<figure><img src="image_6.png" /><figcaption>**Figure 3.** Kaplan–Meier estimates of LRFS (A), PFS (B), OS (C), DSS (D) and MFS (E) in the whole cohort and in patients treated with curative and palliative intent. Survival rates were determined using the Kaplan–Meier method. Survival curves of patients treated with palliative (n = 10) and curative (n = 18) intent were compared using the Grehan–Breslow–Wilcoxon test. RT: radiotherapy, LRFS: local relapse-free survival, PFS: progression-free survival, OS: overall survival, DSS: disease-specific survival, MFS: metastasis-free survival.</figcaption></figure>

Among all women, 8 (29%) remained relapse-free 5 years after the second course of in-field radiation therapy. During the follow-up period, we observed 11 local and 11 metastatic recurrences. Individual data about treatments and outcomes are available in Table 2.
<table><caption>**Table 2.** Individual characteristics of patients: treatments and outcomes.</caption><thead><tr><th>Patient No.</th><th>Age at 2nd RT Course</th><th>Year of 2nd RT Course</th><th>Time from 1st RT Course (Months)</th><th>Site and Dose of Reirradiation (Gy)</th><th>Cumulative Dose to the Breast/Chest Wall (Gy<sub>2</sub>)</th><th>Treatments Besides RT</th><th>Intent</th><th>PFS (Months)</th><th>Progression after 2nd RT Course</th><th>OS (Months)</th></tr></thead><tbody><tr><td>1</td><td>38</td><td>2003</td><td>31</td><td>Chest wall 38</td><td>104</td><td>Mastectomy + adjuvant Capecitabine + Triptorelin + Letrozole</td><td>Palliative</td><td>3</td><td>Unique choroid metastasis</td><td>15</td></tr><tr><td>2</td><td>80</td><td>2003</td><td>24</td><td>Whole Breast 39.6</td><td>115.1</td><td>Adjuvant Vinorelbine + Methotrexate</td><td>Palliative</td><td>5</td><td>Extensive cutaneous lymphangitis</td><td>78</td></tr><tr><td>3</td><td>37</td><td>2003</td><td>18</td><td>Chest wall 50</td><td>110</td><td>Mastectomy + adjuvant Vinorelbine + Methotrexate + Enantone + Anastrozole</td><td>Curative</td><td>15</td><td>Breast cutaneous nodes</td><td>46</td></tr><tr><td>4</td><td>78</td><td>2004</td><td>4</td><td>Chest wall 30</td><td>80</td><td>Continuing Exemestane</td><td>Curative</td><td>60+ (DF)</td><td></td><td>58</td></tr><tr><td>5</td><td>61</td><td>2004</td><td>35</td><td>Chest wall 52, Berg I 46</td><td>118</td><td>Mastectomy + adjuvant Docetaxel + Fulvestrant</td><td>Curative</td><td>68</td><td>Multiple bone metastases</td><td>114+ (A)</td></tr><tr><td>6</td><td>77</td><td>2004</td><td>124</td><td>Chest wall 50, Berg II-IV 48, CMI 48, Boost to the tumor bed 16</td><td>116</td><td>Mastectomy</td><td>Curative</td><td>9</td><td>Chest wall recurrence</td><td>34</td></tr><tr><td>7</td><td>79</td><td>2005</td><td>11</td><td>Whole breast 20</td><td>70</td><td>Adjuvant Capecitabine + Tamoxifen</td><td>Palliative</td><td>1,0</td><td>Out-of-field breast cutaneous nodes</td><td>32</td></tr><tr><td>8</td><td>54</td><td>2005</td><td>98</td><td>Chest wall 48</td><td>98</td><td>Partial mastectomy</td><td>Palliative</td><td>203+ (DF)</td><td></td><td>203+ (A)</td></tr><tr><td>9</td><td>83</td><td>2005</td><td>10</td><td>Whole breast 13 (2 × 6.5)</td><td>86.5</td><td>Concurrent and adjuvant Exemestane</td><td>Palliative</td><td>126</td><td>Metastatic pleurisy</td><td>7</td></tr><tr><td>10</td><td>60</td><td>2005</td><td>45</td><td>Chest wall 46</td><td>110</td><td>Partial mastectomy + adjuvant Docetaxel + 5FU + Letrozole</td><td>Curative</td><td>26</td><td>Controlateral axillary adenopathies</td><td>90</td></tr><tr><td>11</td><td>45</td><td>2008</td><td>130</td><td>Chest wall 20</td><td>70</td><td>Mastectomy + axillary lymph node resection + adjuvant Docetaxel + Bevacizumab</td><td>Curative</td><td>3</td><td>Inguinal adenopathy</td><td>22</td></tr><tr><td>12</td><td>78</td><td>2009</td><td>14</td><td>Whole breast 10 (2 × 5)</td><td>49.6</td><td>Adjuvant Navelbine + Trastuzumab</td><td>Palliative</td><td>12</td><td>Breast cutaneous nodes</td><td>24</td></tr><tr><td>13</td><td>73</td><td>2009</td><td>19</td><td>Chest wall 48</td><td>114</td><td>Neoadjuvant Paclitaxel + Bevacizumab + mastectomy + axillary lymph node resection</td><td>Palliative</td><td>11</td><td>Lung metastases and multiple mediastinal adenopathies</td><td>18</td></tr><tr><td>14</td><td>64</td><td>2010</td><td>94</td><td>Chest wall 48</td><td>114</td><td>Mastectomy + adjuvant Docetaxel + Cyclophosphamide</td><td>Palliative</td><td>15</td><td>Lung metastasis</td><td>37</td></tr></tbody></table>
<table><caption>Table 2. *Cont.*</caption><thead><tr><th>Patient No.</th><th>Age at 2nd RT Course</th><th>Year of 2nd RT Course</th><th>Time from 1st RT Course (Months)</th><th>Site and Dose of Reirradiation (Gy)</th><th>Cumulative Dose to the Breast/Chest Wall (Gy<sub>2</sub>)</th><th>Treatments Besides RT</th><th>Intent</th><th>PFS (Months)</th><th>Progression after 2nd RT Course</th><th>OS (Months)</th></tr></thead><tbody><tr><td>15</td><td>89</td><td>2010</td><td>67</td><td>Chest wall 20</td><td>77.6</td><td>Partial mastectomy + adjuvant Exemestane</td><td>Curative</td><td>44</td><td>Unique intramuscular metastasis of the trapezius</td><td>45</td></tr><tr><td>16</td><td>78</td><td>2010</td><td>91</td><td>Chest wall 50</td><td>115</td><td>Partial mastectomy + adjuvant Anastrozole</td><td>Curative</td><td>15</td><td>Unique field presternal cutaneous node</td><td>42+ (A)</td></tr><tr><td>17</td><td>75</td><td>2011</td><td>109</td><td>Chest wall 50, Berg II- IV 46, CMI 48</td><td>101</td><td>Mastectomy + adjuvant FEC100 then Docetaxel + Letrozole</td><td>Curative</td><td>72+ (DF)</td><td></td><td>72 (A)</td></tr><tr><td>18</td><td>61</td><td>2012</td><td>111</td><td>Whole breast 30</td><td>96</td><td>Axillary lymph node resection + adjuvant Docetaxel + Fulvestrant</td><td>Palliative</td><td>6</td><td>Breast recurrence</td><td>13*</td></tr><tr><td>19</td><td>37</td><td>2013</td><td>34</td><td>Chest wall 46</td><td>92</td><td>Mastectomy + sentinel lymph node biopsy + adjuvant Docetaxel + Cyclophosphamide + Triptorelin</td><td>Curative</td><td>103</td><td>Multiple bone metastases</td><td>109+ (A)</td></tr><tr><td>20</td><td>50</td><td>2014</td><td>49</td><td>Chest wall 30, Berg II- IV 46, CMI 46</td><td>96</td><td>Mastectomy + adjuvant FEC100 then Docetaxel + Enantone + Letrozole</td><td>Curative</td><td>86+ (DF)</td><td></td><td>86+ (A)</td></tr><tr><td>21</td><td>51</td><td>2015</td><td>36</td><td>Chest wall 48, Berg II-IV 40, CMI 40</td><td>96</td><td>Mastectomy + axillary lymph node resection + adjuvant Trastuzumab + Pertuzumab</td><td>Curative</td><td>21</td><td>Breast recurrence and multiple mediastinal adenopathies</td><td>85</td></tr><tr><td>22</td><td>62</td><td>2015</td><td>92</td><td>Chest wall 45</td><td>97</td><td>Partial mastectomy + adjuvant Docetaxel + Trastuzumab + Pertuzumab</td><td>Curative</td><td>88+ (DF)</td><td></td><td>88+ (A)</td></tr><tr><td>23</td><td>72</td><td>2016</td><td>38</td><td>Chest wall 50</td><td>100</td><td>Mastectomy + adjuvant Letrozole</td><td>Curative</td><td>30</td><td>Chest wall recurrence</td><td>76+ (A)</td></tr><tr><td>24</td><td>46</td><td>2017</td><td>138</td><td>Whole breast 50</td><td>118</td><td>Adjuvant Capecitabine + Trastuzumab + Pertuzumab + Tamoxifene</td><td>Palliative</td><td>22</td><td>Breast cutaneous nodes</td><td>49</td></tr><tr><td>25</td><td>82</td><td>2017</td><td>149</td><td>Chest wall 48, Berg I-IV 48</td><td>98</td><td>Mastectomy + sentinel lymph node biopsy + adjuvant Exemestane</td><td>Curative</td><td>18</td><td>Chest wall recurrence</td><td>63+ (A)</td></tr><tr><td>26</td><td>42</td><td>2019</td><td>7</td><td>Partial breast 26</td><td>76</td><td>-</td><td>Curative</td><td>43+ (DF)</td><td></td><td>43+ (A)</td></tr></tbody></table>
<table><caption>Table 2. *Cont.*</caption><thead><tr><th>Patient No.</th><th>Age at 2nd RT Course</th><th>Year of 2nd RT Course</th><th>Time from 1st RT Course (Months)</th><th>Site and Dose of Reirradiation (Gy)</th><th>Cumulative Dose to the Breast/Chest Wall (Gy<sub>2</sub>)</th><th>Treatments Besides RT</th><th>Intent</th><th>PFS (Months)</th><th>Progression after 2nd RT Course</th><th>OS (Months)</th></tr></thead><tbody><tr><td>27</td><td>42</td><td>2019</td><td>123</td><td>Chest wall 50</td><td>116</td><td>mastectomy + sentinel lymph node biopsy + adjuvant Tamoxifene</td><td>Curative</td><td>18</td><td>Multiple supra and infradiaphragmatic adenopathies</td><td>37+ (A)</td></tr><tr><td>28</td><td>71</td><td>2019</td><td>142</td><td>Whole breast 50, Berg II- IV 50, CMI 50</td><td>116</td><td>Partial mastectomy + adjuvant Letrozole</td><td>Curative</td><td>42+ (DF)</td><td></td><td>42+ (A)</td></tr></tbody></table>

<footnote>* Died of myocardial infarction 13 months after RT, RT: radiotherapy, Gy: Gray, PFS: progression-free survival, OS: overall survival, DF: disease-free at last visit, A: alive.</footnote>
4. Discussion

This single-centre series has shown that with decreasing recurrence, reirradiation of
the treated volumes is a rare condition, but it represents a feasible treatment option with an
acceptable rate of side effects and could improve patient outcomes.

Even though approximately 3–8% of patients with breast cancer eventually develop an ipsilateral breast recurrence [1], we only identified 28 patients (0.13%) among the 21,372 who received a first breast irradiation in our institution and who underwent in-field reirradiation for their breast or chest wall recurrence. Reirradiation is a heterogeneous and centre-dependent practice [3], and the management of local recurrence relies mainly on surgery in our institution. Recently, the Italian Association of Radiotherapy and Clinical Oncology (AIRO) found that only a third of radiation therapy centres in Italy [15] propose breast/chest wall reirradiation, highlighting concerns about its feasibility, efficacy and toxicity.

In our series, we report favourable outcomes for reirradiation, similar to other retro-
spective studies obtained with various radiation therapy regimens, doses and techniques,
with 58.9% LRFS and 81.6% OS at 2 years. As expected, the results were particularly satis-
factory in women treated for curative purposes, with a 2-year LRFS of 72% and a 2-year OS
of 94%. These results were comparable to those found by Fattahi et al. in 72 patients [6].
The 2-year LRFS was 93.1%, and the 2-year OS was 76.8% for those treated with curative
intent without gross disease at reirradiation and 57.1% and 71.4% in those treated with
curative intent with gross disease [6].

A further noteworthy result was the identification of 8 (29%) long-term responders, with no recurrence at 5 years after the second radiation therapy. This suggests that some patients may particularly benefit from reirradiation, raising the issue of patient selection. Identifying predictive factors of response to reirradiation seems important, but data available in the literature on reirradiation are mainly based on modest, heterogeneous retrospective series, making subgroup analyses complex. There is mostly reported experience of partial breast irradiation in cases of recurrence. One of the largest reported series is the GEC ESTRO experience, reported by Hannoun-Levi et al., who retrospectively gathered data across seven European centres from patients who underwent a second conservative treatment combining lumpectomy and accelerated partial breast reirradiation (APBrI) using brachytherapy [16]. In the 508 included patients, APBrI was effective and well tolerated, and GEC-ESTRO APBI classification was recorded as an independent prognostic factor. Tumor size (>20 mm) may also represent another valuable prognostic factor [7,17]. These findings may be useful to patients and physicians for choosing between conservative and radical treatments in the decision-making process.

Different approaches are currently proposed to improve the outcomes and toxicity of patients who require reirradiation. The NRG Oncology/RTOG 1014 phase 2 trial demonstrated that partial breast reirradiation delivering 1.5 Gy twice daily for 15 days (45 Gy) was associated with low rates of locoregional recurrence and toxicity in 58 patients [2]. Hyperthermia combined with RT may also be an interesting treatment for locally recurrent breast cancer [18]. A meta-analysis from Datta et al. showed that the combination improved the complete response compared to RT alone [19]. Proton reirradiation could also represent a valuable option, with good outcomes and acceptable toxicity [12,20]. Despite the accumulation of data, the best RT regimen and technique to propose for breast/chest wall reirradiation remains unknown. Further prospective data are expected from various studies currently underway to clarify the grey areas [21–23].

In the presented series, one patient died from myocardial infarction during the follow-
up period. This patient was heavily pretreated for bilateral recurrent breast cancer and
presented with multiple comorbidities and factors at risk. As this death occurred af-
ter left breast reirradiation (mean heart dose = 6.86 Gy), we reported her case as grade
5 treatment-related toxicity, even though it may be at least in part explained by other con-
founding factors, as the patient had multiple cardiovascular risk factors and had received
antracycline-based chemotherapy. It is well known that cardiac toxicity is very complex
and multifactorial [24]. In the case of this patient, the first breast irradiation was realized
in the lateral position using a specific technique, as previously described, and the heart
dose was close to 0 Gy [25]. This technique of whole breast radiotherapy in the lateral
decubitus position for patients with large breasts and early-stage breast cancer provides an
excellent dosimetric profile, with low doses to the heart and ipsilateral lung. It is also very
well tolerated, with a good acute toxicity profile, and was chosen in the case of this patient
because of her comorbidities.

In the reported series, the other patients experienced a low rate of acute and late AEs, with 3.5% of acute and late grade 3 AEs and mainly skin toxicity. Given the small number of events, a search for toxicity-associated factors was not possible. Toxicity rates vary greatly in the literature [3], depending on the characteristics of reirradiation (particle used, irradiated sites, dose, etc.), with grade 3 AEs ranging between 0% [9] and 30% [18] between series. Comparisons between cohorts are difficult, but altogether, these data suggest that reirradiation is feasible.

This work has several limitations, mainly due to the small size and heterogeneity of the
population. Some patients were treated with breast-conserving surgery, and others were
treated with mastectomy. Another limitation is the retrospective nature of our study. At the
same time, these series with long-term results show the feasibility of in-field reirradiation,
even when patients were treated with large target volumes. With the modern techniques of
radiation therapy, better results can be expected.

These real-life data add to the growing body of evidence supporting that reirradiation
may be an appropriate treatment for patients requiring locoregional treatment in previously
irradiated sites and could be a new chance to cure these patients. This treatment option
could be considered an individualized treatment for many patients with locally recurrent
breast cancer.

**5. Conclusions**

Breast or chest wall reirradiation appears to be feasible with good disease control,
especially in patients treated with a curative intent, and acceptable toxicity rates. In
addition, a significant number of patients were disease-free 5 years after the second course
of RT. Prospective larger data with longer follow-up are needed to confirm these findings.

**Supplementary Materials:** The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/cancers15184515/s1, Figure S1: Kaplan-Meier estimates of LRFS for reirradiation according to the efficacy of the first course of RT; Figure S2: Kaplan-Meier estimates of LRFS for reirradiation according to the time between RT courses.

**Author Contributions:** Conceptualization, J.B. and Y.K.; methodology, J.B. and Y.K.; validation, R.D., K.C., A.F. and Y.K.; formal analysis, J.B.; investigation, J.B.; writing—original draft preparation, J.B.; writing—review and editing, J.B., A.F. and Y.K.; supervision, Y.K. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki.

**Data Availability Statement:** Data supporting reported results can be provided by the corresponding author upon reasonable request.

**Conflicts of Interest:** The authors declare no conflict of interest.
## References

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG); Darby, S.; McGale, P.; Correa, C.; Taylor, C.; Arriagada, R.; Clarke, M.; Cutter, D.; Davies, C.; Ewertz, M.; et al. Effect of Radiotherapy after Breast-Conserving Surgery on 10-Year Recurrence and 15-Year Breast Cancer Death: Meta-Analysis of Individual Patient Data for 10,801 Women in 17 Randomised Trials. *Lancet* **2011**, *378*, 1707–1716. [CrossRef] [PubMed]

2. Arthur, D.W.; Winter, K.A.; Kuerer, H.M.; Haffty, B.; Cuttino, L.; Todor, D.A.; Anne, P.R.; Anderson, P.; Woodward, W.A.; McCormick, B.; et al. Effectiveness of Breast-Conserving Surgery and 3-Dimensional Conformal Partial Breast Reirradiation for Recurrence of Breast Cancer in the Ipsilateral Breast: The NRG Oncology/RTOG 1014 Phase 2 Clinical Trial. *JAMA. Oncol.* **2020**, *6*, 75–82. [CrossRef]

3. Abeloos, C.H.; Purswani, J.M.; Galavis, P.; McCarthy, A.; Hitchen, C.; Choi, J.I.; Gerber, N.K. Different Re-Irradiation Techniques after Breast-Conserving Surgery for Recurrent or New Primary Breast Cancer. *Curr. Oncol.* **2023**, *30*, 1151–1163. [CrossRef] [PubMed]

4. Mullen, E.E.; Deutsch, M.; Bloomer, W.D. Salvage Radiotherapy for Local Failures of Lumpectomy and Breast Irradiation. *Radiother. Oncol.* **1997**, *42*, 25–29. [CrossRef]

5. Deutsch, M. Repeat High-Dose External Beam Irradiation for in-Breast Tumor Recurrence after Previous Lumpectomy and Whole Breast Irradiation. *Int. J. Radiat. Oncol. Biol. Phys.* **2002**, *53*, 687–691. [CrossRef] [PubMed]

6. Fattahi, S.; Ahmed, S.K.; Park, S.S.; Petersen, I.A.; Shumway, D.A.; Stish, B.J.; Yan, E.S.; Remmes, N.B.; Mutter, R.W.; Corbin, K.S. Reirradiation for Locoregional Recurrent Breast Cancer. *Adv. Radiat. Oncol.* **2021**, *6*, 100640. [CrossRef]

7. Oldenborg, S.; Griesdoorn, V.; van Os, R.; Kusumanto, Y.H.; Oei, B.S.; Venselaar, J.L.; Zum Vörde Sive Vörding, P.J.; Heymans, M.W.; Kolff, M.W.; Rasch, C.R.N.; et al. Reirradiation and Hyperthermia for Irresectable Locoregional Recurrent Breast Cancer in Previously Irradiated Area: Size Matters. *Radiother. Oncol.* **2015**, *117*, 223–228. [CrossRef]

8. Linthorst, M.; van Geel, A.N.; Baaijens, M.; Ameziane, A.; Ghidey, W.; van Rhoon, G.C.; van der Zee, J. Re-Irradiation and Hyperthermia after Surgery for Recurrent Breast Cancer. *Radiother. Oncol.* **2013**, *109*, 188–193. [CrossRef]

9. Janssen, S.; Rades, D.; Meyer, A.; Fahlbusch, F.B.; Wildfang, I.; Meier, A.; Schild, S.; Christiansen, H.; Henkenberens, C. Local Recurrence of Breast Cancer: Conventionally Fractionated Partial External Beam Re-Irradiation with Curative Intention. *Strahlenther. Onkol.* **2018**, *194*, 806–814. [CrossRef]

10. Chen, I.; Botty Van den Bruele, A.M.; Gillespie, E.F.; Mueller, B.A.; Xu, A.J.; Cuaron, J.; Khan, A.J.; McCormick, B.; Cahlon, O.; Powell, S.N.; et al. Salvage of Locally Recurrent Breast Cancer with Repeat Breast Conservation Using 45 Gy Hyperfractionated Partial Breast Re-Irradiation. *Breast Cancer Res. Treat.* **2021**, *188*, 409–414. [CrossRef]

11. Thorpe, C.S.; Niska, J.R.; Girardo, M.E.; Kosiorek, H.E.; McGee, L.A.; Hartsell, W.F.; Larson, G.L.; Tsai, H.K.; Rossi, C.J.; Rosen, L.R.; et al. Proton Beam Therapy Reirradiation for Breast Cancer: Multi-Institutional Prospective PCG Registry Analysis. *Breast J.* **2019**, *25*, 1160–1170. [CrossRef]

12. LaRiviere, M.J.; Dreyfuss, A.; Taunk, N.K.; Freedman, G.M. Proton Reirradiation for Locoregionally Recurrent Breast Cancer. *Adv. Radiat. Oncol.* **2021**, *6*, 100710. [CrossRef] [PubMed]

13. Hannoun-Levi, J.-M.; Gal, J.; Schiappa, R.; Chand, M.-E. 10-Year Oncological Outcome Report after Second Conservative Treatment for Ipsilateral Breast Tumor Event. *Clin. Transl. Radiat. Oncol.* **2023**, *38*, 71–76. [CrossRef] [PubMed]

14. START Trialists' Group; Bentzen, S.M.; Agrawal, R.K.; Aird, E.G.; Barrett, J.M.; Barrett-Lee, P.J.; Bliss, J.M.; Brown, J.; Dewar, J.A.; Dobbs, H.J.; et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: A Randomised Trial. *Lancet Oncol.* **2008**, *9*, 331–341. [CrossRef]

15. Massaccesi, M.; Fontana, A.; Palumbo, I.; Argenone, A.; De Santis, M.C.; Masiello, V.; Pontoriero, A.; Ciabattoni, A. Pattern of Practice of Re-Irradiation for Ipsilateral Breast Tumor Recurrence in Italy: A Survey by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). *Clin. Transl. Oncol.* **2023**. [CrossRef]

16. Hannoun-Levi, J.-M.; Gal, J.; Polgar, C.; Strnad, V.; Loessl, K.; Polat, B.; Kauer-Domer, D.; Schiappa, R.; Gutierrez, C. GEC-ESTRO Breast Cancer Working Group Second Conservative Treatment for Local Recurrence Breast Cancer: A GEC-ESTRO Oncological Outcome and Prognostic Factor Analysis. *Int. J. Radiat. Oncol. Biol. Phys.* **2023**, *S0360-3016(23)02194-6*. [CrossRef]

17. Montagne, L.; Gal, J.; Chand, M.-E.; Schiappa, R.; Falk, A.T.; Kinj, R.; Gauthier, M.; Hannoun-Levi, J.-M. GEC-ESTRO APBI Classification as a Decision-Making Tool for the Management of 2nd Ipsilateral Breast Tumor Event. *Breast Cancer Res. Treat.* **2019**, *176*, 149–157. [CrossRef] [PubMed]

18. Schouten, D.; van Os, R.; Westermann, A.M.; Crezee, H.; van Tienhoven, G.; Kolff, M.W.; Bins, A.D. A Randomized Phase-II Study of Reirradiation and Hyperthermia versus Reirradiation and Hyperthermia plus Chemotherapy for Locally Recurrent Breast Cancer in Previously Irradiated Area. *Acta. Oncol.* **2022**, *61*, 441–448. [CrossRef] [PubMed]

19. Datta, N.R.; Puric, E.; Klingbiel, D.; Gomez, S.; Bodis, S. Hyperthermia and Radiation Therapy in Locoregional Recurrent Breast Cancers: A Systematic Review and Meta-Analysis. *Int. J. Radiat. Oncol. Biol. Phys.* **2016**, *94*, 1073–1087. [CrossRef]

20. Choi, J.I.; Khan, A.J.; Powell, S.N.; McCormick, B.; Lozano, A.J.; Del Rosario, G.; Mamary, J.; Liu, H.; Fox, P.; Gillespie, E.; et al. Proton Reirradiation for Recurrent or New Primary Breast Cancer in the Setting of Prior Breast Irradiation. *Radiother. Oncol.* **2021**, *165*, 142–151. [CrossRef]

21. Loap, P.; Beddok, A.; Cao, K.I.; Goudjil, F.; Fourquet, A.; Dendale, R.; Kirova, Y. Clinical Practice of Breast Cancer Protontherapy: A Single-Centre Experience from Selection to Treatment. *Cancer Radiother. Oncol.* **2021**, *25*, 358–365. [CrossRef] [PubMed]
22. Weill Medical College of Cornell University. Personalized Second Chance Breast Conservation (PSCBC): A Two Center Prospective Phase II Clinical Study. 2023. Available online: [clinicaltrials.gov](http://clinicaltrials.gov) (accessed on 6 September 2023).

23. Proton Collaborative Group. Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer. 2023. Available online: [clinicaltrials.gov](http://clinicaltrials.gov) (accessed on 6 September 2023).

24. Kirova, Y.; Tallet, A.; Aznar, M.C.; Loap, P.; Bouali, A.; Bourgier, C. Radio-Induced Cardiotoxicity: From Physiopathology and Risk Factors to Adaptation of Radiotherapy Treatment Planning and Recommended Cardiac Follow-Up. *Cancer Radiother. 2020*, *24*, 576–585. [CrossRef] [PubMed]

25. Kirova, Y.M.; Hijal, T.; Campana, F.; Fournier-Bidoz, N.; Stilhart, A.; Dendale, R.; Fourquet, A. Whole Breast Radiotherapy in the Lateral Decubitus Position: A Dosimetric and Clinical Solution to Decrease the Doses to the Organs at Risk (OAR). *Radiother. Oncol.* **2014**, *110*, 477–481. [CrossRef] [PubMed]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.